Results 51 to 60 of about 1,998,403 (289)

The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review

open access: yesOphthalmology and Therapy
Introduction Immune checkpoint inhibitors have made tremendous progress over the last decade in the treatment of cutaneous melanoma, but their application in uveal melanoma treatment is less successful, owing in part to the immunological privilege of the
Jinyu Wang, Zehua Li, Hongbo Yin
doaj   +1 more source

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

open access: yesFEBS Letters, EarlyView.
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos   +9 more
wiley   +1 more source

Supplementary Table S1: Combination therapies in clinical trials involving immune checkpoint inhibitors from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

open access: yes, 2018
Supplementary Table S1 summarizes clinical trials of combinatorial therapies that include immune checkpoint inhibitors. This includes combined immune checkpoint blockade, as well as the combination of immune checkpoint inhibitors with radiotherapy, and ...
Richard A. Scolyer (8553126)   +3 more
core   +1 more source

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma

open access: yes, 2020
Despite the advances in screening protocols and treatment options, hepatocellular carcinoma (HCC) is still considered to be the most lethal malignancy in patients with liver cirrhosis.
Samer Saadi   +7 more
core   +1 more source

Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Carcinoma: Current Status [PDF]

open access: yes, 2018
Introduction: Large cell neuroendocrine carcinomas (LCNEC) are a group of rare high grade neuroendocrine tumors that often behave clinically like small cell carcinoma (SCLC) and are treated as such.
Jill Kolesar   +11 more
core   +1 more source

The ubiquitin system in normal and infected germinal center B cells

open access: yesFEBS Letters, EarlyView.
The ubiquitin system plays a central role in germinal center (GC) B cells, influencing differentiation to long‐lived memory B cells. Oncogenic gammaherpesviruses gain access to memory B cells by establishing latency in GC B cells. Mapping ubiquitin mechanisms in normal and infected GC B cells will define specific molecular circuits in B cells germane ...
Destiny Davis   +2 more
wiley   +1 more source

Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer

open access: yes, 2016
Advanced non-small-cell lung cancer (NSCLC) has a poor prognosis with few treatment options available for patients after failure of first-line therapy.
O'Byrne, Kenneth J., Decatris, Marios P.
core   +1 more source

Metastatic niche shaped by host factors influences disseminated cancer cell fate

open access: yesFEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward   +2 more
wiley   +1 more source

Efficacy of immune checkpoint inhibitors in different types of melanoma

open access: yes, 2021
Immunotherapy can be used for cutaneous, mucosal, uveal and conjunctival melanoma. Nevertheless, we cannot expect the same benefit from checkpoint inhibitors for all the types of melanoma.
Ernesto Rossi   +15 more
core   +2 more sources

Progress of Biomarkers to Predict Response to Immune Checkpoint Inhibitors in Microsatellite Stability Colorectal Cancer

open access: yesZhongliu Fangzhi Yanjiu, 2023
The exploration of biomarkers predicting response to immune checkpoint inhibitors in microsatellite stability colorectal cancer can enable more patients to benefit from immunotherapy.
WANG Zhiqiang   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy